Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLL
354 views · Published 15 December 2015 · 5:56 · Indexed 27 October 2026
Channel: American Society of Hematology · 2015 · Nonprofits & Activism
Alesssandra Tedeschi, MD, shares the results of the RESONATE 2 trial, which found that ibrutinib was superior to conventional chemotherapy as a first-line treatment for older patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding